Brain Imaging Study of Speech Decline in Apraxia of Speech
Studies brain scans and speech changes over time in people with progressive apraxia of speech.
Plain-language title generated from the registry record
Registry title: Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech
Key facts
- Where
- Rochester, United StatesSee the site
- Phase
- Phase 4
Where in United States
- Mayo ClinicRochester, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mayo Clinic
- Trial code
- NCT01818661
- Record updated
- 12 November 2025
- Original description
The study is designed to determine the relationship between structural and functional changes in the brain on imaging and progression of speech and language, neurological and neuropsychological features in patients with neurodegenerative apraxia of speech (AOS).Read full original descriptionShow less
Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech
The study is designed to determine the relationship between structural and functional changes in the brain on imaging and progression of speech and language, neurological and neuropsychological features in patients with neurodegenerative apraxia of speech (AOS).
Inclusion: We will study subjects that fulfill clinical inclusion criteria for neurodegenerative AOS that have been seen and diagnosed at Mayo Clinic.
Exclusion: Subjects with concurrent illnesses that could account for speech and language deficits, such as traumatic brain injury, strokes or developmental syndromes will be excluded; Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism,(e.g. chemotherapy); Women that are pregnant or post-partum and breast-feeding will be excluded. All women who can become pregnant must have a pregnancy test no more than 48 hours before the PET scan; Subjects will also be excluded if they do not have an informant, or do not consent to research.